Facts About Asthma
Understand more about what asthma is, how asthma is diagnosed and what you can do to reduce symptoms in your day to day life.
Search
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
International recognition for Boehringer Ingelheim BioXcellence™
International recognition for Boehringer Ingelheim BioXcellence™
Research-collaboration-Gubra-obesity-treatment
Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.
trust-through-transparency
Transparency is an essential cornerstone of trust in the healthcare industry
Boehringer expands cancer research at Vienna site
Boehringer Ingelheim expands cancer research at its Vienna site
It is about saving lives Alexis Jaliquias feline blood bank
Veterinarian Alexis Jaliquias founded one of the first blood banks for cats in South America
Partnering with Lifebit to detect global disease outbreaks
Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaks
BI Focuses COVID-19 Clinical Research on Alteplase
BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems
Vaccine bluetongue virus serotype 3 sheep cattle
BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
Avian influenza 5 things you should know
Communities across the globe are faced with outbreaks of bird flu. We stand with poultry farmers and veterinarians and supports the effort against the disease
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
Partnering with Boehringer Ingelheim at BIO-Europe 2024
Learn about partnering with Boehringer Ingelheim at BIO-Europe 2024 and how together we can accelerate innovation in human health
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
preserved-heart-failure-treatment-FDA-US-approval
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
New production center for Veterinary Public Health
Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.
PRRS vaccine celebrates 25 years in Europe
Boehringer Ingelheim celebrates 25 years to combat PRRS in Europe
Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Accelerating new cancer medicines in partnership with CBmed
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
Fabio Paganini fostering inclusion & agility in AH
How employees are contributing to an inclusive culture at Boehringer Ingelheim.
Phase II trial results in people living with obesity or overweight
Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
Partnership-with-clicktherapeutics
Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia